Cyclopamine

Name: Cyclopamine
Brand: Selleck Chemicals
SKU: S1146
Rating: 5 (32 reviews)

For research use only. Not for use in humans.

Catalog No.S1146 Synonyms: 11-deoxojervine

32 publications

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Selleck's Cyclopamine has been cited by 32 publications

Nature, 2015, 10.1038/nature14325

PubMed: 25938716 ( click the link to review the publication )

Nat Commun, 2020, 11(1):44

PubMed: 31896750 ( click the link to review the publication )

J Cell Physiol, 2019, 234(3):2058-2066

PubMed: 30317648 ( click the link to review the publication )

Phytomedicine, 2019, 67:153163

PubMed: 31901891 ( click the link to review the publication )

Exp Cell Res, 2019, 385(2):111671

PubMed: 31634481 ( click the link to review the publication )

Neuron, 2018, 97(6):1235-1243

PubMed: 29526553 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 30014845 ( click the link to review the publication )

Exp Cell Res, 2018, 366(1):63-70

PubMed: 29548749 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):21-30

PubMed: 29115520 ( click the link to review the publication )

Nat Commun, 2017, 8:14382

PubMed: 28176763 ( click the link to review the publication )

Front Immunol, 2017, 9:2847

PubMed: 30568656 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Exp Cell Res, 2017, 357(1):79-87

PubMed: 28461158 ( click the link to review the publication )

Cell Biosci, 2016, 10.1186/s13578-016-0104-8

PubMed: 27313840 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6626-38

PubMed: 26675547 ( click the link to review the publication )

J Hematol Oncol, 2015, 8:63

PubMed: 26048374 ( click the link to review the publication )

Stem Cell Reports, 2015, 5(5):816-828

PubMed: 26527387 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(9):2569-89

PubMed: 26609469 ( click the link to review the publication )

Mol Carcinog, 2015, 10.1002/mc.22300

PubMed: 25728352 ( click the link to review the publication )

Eur J Pharmacol, 2014, 10.1016/j.ejphar.2014.01.074

PubMed: 24534491 ( click the link to review the publication )

Mol Cell Biochem, 2014, 396(1-2):257-68

PubMed: 25064451 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbadis.2014.10.001

PubMed: 25305367 ( click the link to review the publication )

Insect Sci, 2014, 10.1111/1744-7917

PubMed: 25154865 ( click the link to review the publication )

Dev Biol, 2013, 381(2):312-23

PubMed: 23872235 ( click the link to review the publication )
Liver Int, 2013, 33(1):149-61

PubMed: 23121638 ( click the link to review the publication )

Toxicol Lett, 2013, 225(2):318-324

PubMed: 24388991 ( click the link to review the publication )

PLoS One, 2013, 8(3):e57346

PubMed: 23483902 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Neuro Oncol, 2012, 14(12):1441-51

PubMed: 23104476 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2262-74

PubMed: 22396494 ( click the link to review the publication )

Cancer Lett, 2012, 322(2):169-76

PubMed: 22450749 ( click the link to review the publication )

Exp Hematol, 2012, 40(5):418-27

PubMed: 22240607 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Targets

Smoothened ^[1]
(TM3Hh12 cells)

46 nM

In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [³H]Hh-Ag binding assay with an IC50 of 280 nM. ^[1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. ^[2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMO^high Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMO^low cell line. ^[3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
OS-RC-2	NWnzfY9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjWeoFKSzVyPUWuPFY3PiEQvF2=	MX7TRW5ITVJ?
DOHH-2	M1LQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonaTWM2OD17LkO1Olg6KM7:TR?=	Mo\ZV2FPT0WU
no-10	MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LmfmlEPTB;OT65NFM6KM7:TR?=	NY\xTnpOW0GQR1XS
LS-513	NUfke206T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELTTXpKSzVyPUGxMlM2PDdizszN	MXfTRW5ITVJ?
ALL-PO	NUPRbmtIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrqS2FmUUN3ME2xNU44PzN2IN88US=>	NF;1bWtUSU6JRWK=
8-MG-BA	NYe4TFFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2L2eGlEPTB;MUOuNVEzOyEQvF2=	NWLlcY9WW0GQR1XS
RPMI-8402	Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonOTWM2OD1zNT64OVM4KM7:TR?=	NV24bXU5W0GQR1XS
EoL-1-cell	NUfPUoxZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LKT2lEPTB;MUiuOVk1QCEQvF2=	NHH6W4pUSU6JRWK=
NALM-6	M1v4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPrTWM2OD1zOT6wNVY4KM7:TR?=	MX;TRW5ITVJ?
DEL	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XZN2lEPTB;MkCuNVQ4OSEQvF2=	NGTqTYdUSU6JRWK=
SR	NHPOc\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzoTWM2OD1{Mz62O\|E2KM7:TR?=	MWHTRW5ITVJ?
697	Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1viOWlEPTB;Mk[uOlE2PSEQvF2=	NXP0SoxzW0GQR1XS
COLO-829	M2L6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDTUINmUUN3ME2yOk45PDh\|IN88US=>	NVjGRYNpW0GQR1XS
EVSA-T	Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PROWlEPTB;MkeuOVU3OSEQvF2=	MYHTRW5ITVJ?
ATN-1	Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HmfWlEPTB;M{GuNlMzQSEQvF2=	NGfIXFVUSU6JRWK=
L-363	M3raWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TOR2lEPTB;M{GuO\|Q3OSEQvF2=	NELP[2JUSU6JRWK=
LAMA-84	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTN{LkWyNVEh\|ryP	NXm3VnI3W0GQR1XS
NOS-1	M2r6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTN2LkK5OVYh\|ryP	Mmr4V2FPT0WU
BB30-HNC	M2rjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\sOGlEPTB;M{SuN\|MxPiEQvF2=	NYr2VnhkW0GQR1XS
BC-1	NYKxfWplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPx[Yc3UUN3ME2zO{46PzR4IN88US=>	MkXyV2FPT0WU
IST-SL2	MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTN6LkKyOEDPxE1?	NH;jSZNUSU6JRWK=
D-392MG	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYn1cIVRUUN3ME20NE4zOjF3IN88US=>	MUfTRW5ITVJ?
no-11	MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWP2PZp1UUN3ME20NE42PTJzIN88US=>	NF\Ve4lUSU6JRWK=
LC4-1	M{fVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvmUXFKSzVyPUSwMlg4OTZizszN	MVnTRW5ITVJ?
A388	NGfLNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF71V4lKSzVyPUSyMlU5PDhizszN	NUj0NVVoW0GQR1XS
NTERA-S-cl-D1	NXywdnRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LPN2lEPTB;NEKuO\|A4PCEQvF2=	NF61bW5USU6JRWK=
CESS	Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDZTWM2OD12ND6yNlMzKM7:TR?=	NVPq[4RyW0GQR1XS
RS4-11	M{\NZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLiOZNVUUN3ME20PU4xQTN6IN88US=>	NVrK[lZ2W0GQR1XS
MS-1	NXHOZ4pIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\xPW5YUUN3ME21NE46OzVzIN88US=>	NFrOVYZUSU6JRWK=
CTV-1	Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHKTWM2OD13MT6wO\|Qh\|ryP	M{PhdnNCVkeHUh?=
D-502MG	NEXlXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfsUoZXUUN3ME21NU43OjdzIN88US=>	NF3sNVRUSU6JRWK=
ML-2	MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXUc\|FKSzVyPUWyMlkyQTVizszN	MoDBV2FPT0WU
SK-NEP-1	NWLNcIoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7NTWM2OD13Mz6zPVI{KM7:TR?=	MlXJV2FPT0WU
LOXIMVI	MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vmUWlEPTB;NUOuOVg5PCEQvF2=	NXLtU3NzW0GQR1XS
DJM-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jxdGlEPTB;NU[uN\|M6OSEQvF2=	Mm\qV2FPT0WU
GI-1	MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrHTWM2OD13Nj62NVQ6KM7:TR?=	NE\KO5NUSU6JRWK=
IST-MES1	NG[3b5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfYPG1KSzVyPU[wMlU1QTNizszN	MkLzV2FPT0WU
MV-4-11	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnpTWM2OD14MD62OVM5KM7:TR?=	M3PkXHNCVkeHUh?=
OVCAR-4	M4frNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPsWXZKSzVyPU[zMlU3PTdizszN	MnHYV2FPT0WU
KE-37	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYftdHJRUUN3ME22Ok4zPjZ6IN88US=>	M3jsSXNCVkeHUh?=
D-542MG	NH3D[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33uV2lEPTB;NkiuOFE{PSEQvF2=	NUnGdlJoW0GQR1XS
MHH-PREB-1	NFzueYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fo[WlEPTB;N{KuPFQ1OSEQvF2=	MoXHV2FPT0WU
MRK-nu-1	MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnL1TWM2OD15Mz60O\|A2KM7:TR?=	M331d3NCVkeHUh?=
D-247MG	NEXpZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTd\|LkW0OFIh\|ryP	M{TtOnNCVkeHUh?=
OCI-AML2	Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX:xcndVUUN3ME23Ok46OzZ7IN88US=>	NEG5OHlUSU6JRWK=
LP-1	Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYq4RWFzUUN3ME24Nk45PzNzIN88US=>	NV:zenRiW0GQR1XS
HCC1599	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fBWmlEPTB;OESuNlg{PyEQvF2=	NU\LUYNxW0GQR1XS
KARPAS-45	M163[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYGwTodHUUN3ME24OE43QTl{IN88US=>	NWLCSZQ2W0GQR1XS
BE-13	NV\Cc4hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLJTWM2OD17OT6wOFc4KM7:TR?=	NUjTd3BDW0GQR1XS
GCIY	M2nQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mni5TWM2OD17OT6wPVU1KM7:TR?=	MYXTRW5ITVJ?
BV-173	M4Hyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTFyMD6zNlUh\|ryP	M4j0cnNCVkeHUh?=
LB2518-MEL	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYWwZphEUUN3ME2xNFAvPzh7IN88US=>	NWPsdFZ6W0GQR1XS
KS-1	NXy1XYcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HCTmlEPTB;MUCxMlY{QSEQvF2=	M2LNeXNCVkeHUh?=
MOLT-16	NX7nfmh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTFyND65PFYh\|ryP	NHT1ZWZUSU6JRWK=
NCI-H1770	NFLNSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPMdJRKSzVyPUGwPE44QDRizszN	MXjTRW5ITVJ?
NCI-H82	NUHObFFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTFzMD65O\|Yh\|ryP	NEnyeldUSU6JRWK=
NCCIT	NF3zdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PmUWlEPTB;MUGyMlUzQSEQvF2=	NWjxdngyW0GQR1XS
KALS-1	NVnGSnhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LBTWlEPTB;MUG1Mlk1OSEQvF2=	MVjTRW5ITVJ?
LB2241-RCC	NX\VTWc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzCXHdKSzVyPUGxOk43PzlizszN	Mn7ZV2FPT0WU
HH	Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nDNmlEPTB;MUG3MlM6PSEQvF2=	MUTTRW5ITVJ?
HD-MY-Z	NH;aVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PDcWlEPTB;MUG4MlQ5QCEQvF2=	NHrJcZVUSU6JRWK=
EB-3	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTF{Mz6wPVQh\|ryP	MnXEV2FPT0WU
BL-70	M1LQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mni2TWM2OD1zMkOuNVI4KM7:TR?=	MYDTRW5ITVJ?
K-562	Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDzTWM2OD1zMk[uNlQ2KM7:TR?=	NEXn[GtUSU6JRWK=
HT-144	MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;kd45TUUN3ME2xN\|MvOTZ2IN88US=>	MUjTRW5ITVJ?
PF-382	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHP0NpRKSzVyPUGzOE4{PjFizszN	MUfTRW5ITVJ?
RPMI-8226	Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLDbolKSzVyPUGzOU4xPDVizszN	Mn\OV2FPT0WU
NCI-H1355	Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTF\|NT61PFch\|ryP	M{fZXHNCVkeHUh?=
LXF-289	NX;qTndCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLmO5l[UUN3ME2xN\|kvPzhzIN88US=>	NHLYOY9USU6JRWK=
NCI-H69	NFTQPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LHeGlEPTB;MUSyMlk{OiEQvF2=	MlHyV2FPT0WU
SK-MEL-1	M1LUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjaTWM2OD1zNEeuNVMh\|ryP	Mn3nV2FPT0WU
KARPAS-299	NXrofpNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUf5S\|k2UUN3ME2xOFkvOTJizszN	NH3vNG9USU6JRWK=
GB-1	Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXr3S\|NxUUN3ME2xOFkvOzJ{IN88US=>	NXXlPFNTW0GQR1XS
CMK	NGDmN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;hTGlEPTB;MUS5MlUyPSEQvF2=	MVjTRW5ITVJ?
MPP-89	MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rKcWlEPTB;MUW2MlA{PSEQvF2=	M17YU3NCVkeHUh?=
KU812	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DFPWlEPTB;MU[xMlkxOiEQvF2=	M13p[HNCVkeHUh?=
REH	NG[1bJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\wZ2lEPTB;MU[yMlEzPSEQvF2=	NWjie\|RxW0GQR1XS
NEC8	MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTyTWM2OD1zNkWuNFI3KM7:TR?=	MULTRW5ITVJ?
KP-N-YS	M2exfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTF4OD6zPVUh\|ryP	M{XE[XNCVkeHUh?=
Ramos-2G6-4C10	NIK3S\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTF4OT65NVUh\|ryP	NVfzVJNCW0GQR1XS
Becker	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\YTWM2OD1zN{SuNVgh\|ryP	MonOV2FPT0WU
LB647-SCLC	NVfQdWF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn:xTWM2OD1zN{WuPFQ2KM7:TR?=	Mn7DV2FPT0WU
LU-139	NEPDXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDOWZlCUUN3ME2xO\|gvODF7IN88US=>	MXTTRW5ITVJ?
QIMR-WIL	MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTF5OT62OFYh\|ryP	NH;wZ25USU6JRWK=
NCI-H1395	M1\YOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTF5OT65PVYh\|ryP	NF22eWxUSU6JRWK=
NOMO-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLlTWM2OD1zOEKuPFUh\|ryP	NYKwNppMW0GQR1XS
GI-ME-N	NGHQd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\0WoFFUUN3ME2xPFcvQTZ7IN88US=>	M4H2UXNCVkeHUh?=
KMS-12-PE	NIHxS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTF6OT6yO\|Mh\|ryP	NWP5cFR2W0GQR1XS
Daudi	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnr4TWM2OD1zOUGuNVI5KM7:TR?=	MX7TRW5ITVJ?
LB996-RCC	MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfoTWM2OD1zOUGuOlk6KM7:TR?=	MorRV2FPT0WU
NCI-H2107	MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX:z[3piUUN3ME2xPVMvPzN7IN88US=>	M1rEVnNCVkeHUh?=
SK-PN-DW	NETIVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfMUIZKSzVyPUG5OE44OTlizszN	MnTHV2FPT0WU
MC-CAR	NV7IZm5qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULQSFJGUUN3ME2yNFIvOjV\|IN88US=>	M{DBcHNCVkeHUh?=
SNB75	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TiW2lEPTB;MkKxMlk1KM7:TR?=	NGjDb3FUSU6JRWK=
ES4	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWG0cJA2UUN3ME2yNlMvPzh\|IN88US=>	M1Tv[nNCVkeHUh?=
KARPAS-422	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrpT5doUUN3ME2yNlgvOzV{IN88US=>	MX3TRW5ITVJ?
NCI-H1648	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XtZmlEPTB;MkK5MlQ5QSEQvF2=	NWDBWm5pW0GQR1XS
ES6	MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILqdVVKSzVyPUKzPU41OyEQvF2=	NHv5VWFUSU6JRWK=
KNS-81-FD	NGfle4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTkeI1TUUN3ME2yOFEvOTl5IN88US=>	MYrTRW5ITVJ?
JAR	MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7MTWM2OD1{NU[uNlI2KM7:TR?=	NULiXoZ2W0GQR1XS
NB1	NFPHTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTJ4MD61NVYh\|ryP	NHLxb5ZUSU6JRWK=
D-336MG	NGHWTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLQbZRsUUN3ME2yOlAvPjl6IN88US=>	MnXjV2FPT0WU
BC-3	M4HaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTJ4NT6xO\|gh\|ryP	Mmi5V2FPT0WU
HCC2218	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTJ4Nj60NVUh\|ryP	M3nNdXNCVkeHUh?=
TE-9	Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LFSWlEPTB;Mk[2MlYzPyEQvF2=	M4rvUHNCVkeHUh?=
LB1047-RCC	M{HSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHv4OZRKSzVyPUK2Ok44PTNizszN	MnzzV2FPT0WU
CTB-1	MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIO2TIpKSzVyPUK2PU46PzNizszN	MYrTRW5ITVJ?
NB7	NIfT[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jJWmlEPTB;MkexJO69VQ>?	MVLTRW5ITVJ?
ST486	NYjySJYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWT3c4l7UUN3ME2yO\|cvPDF{IN88US=>	MXjTRW5ITVJ?
HCC1187	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1y3SGlEPTB;MkiyMlgyOSEQvF2=	NGHDenpUSU6JRWK=
NCI-SNU-16	NVvKXG1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LDTGlEPTB;Mki0MlI1QCEQvF2=	MmPNV2FPT0WU
COR-L279	NULnPIpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3oS\|hFUUN3ME2yPVEvPTh2IN88US=>	M{XBVnNCVkeHUh?=
ES8	NE\hXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXy2c3dxUUN3ME2yPVQvOTh{IN88US=>	M2Pl[nNCVkeHUh?=
U-698-M	NYPuVHN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfIe\|d5UUN3ME2yPVgvOjR\|IN88US=>	M{LodnNCVkeHUh?=
HEL	NV\ieXl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nVW2lEPTB;M{C5MlE1QSEQvF2=	MmXDV2FPT0WU
KINGS-1	NHzvVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHSTWM2OD1\|MUCuOlc1KM7:TR?=	M4rQZnNCVkeHUh?=
KY821	NH;lNYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3f2NGlEPTB;M{O2MlU6PSEQvF2=	MnnyV2FPT0WU
MZ1-PC	MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHPTWM2OD1\|NEWuOlE5KM7:TR?=	NXjJVlJYW0GQR1XS
LS-411N	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTN3ND62OkDPxE1?	NEPhbFJUSU6JRWK=
SIG-M5	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rsTWlEPTB;M{W5Mlc5OiEQvF2=	MWnTRW5ITVJ?
HT	NGG3UY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTN4Nz63NVEh\|ryP	NWHoN3d1W0GQR1XS
HC-1	NWnVdJRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVq3[YlnUUN3ME2zOlcvPzh5IN88US=>	M3LSenNCVkeHUh?=
NCI-H1694	M3PQ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2[3XGlEPTB;M{eyMlk{PCEQvF2=	NXPMNWRnW0GQR1XS
BB65-RCC	NXzZZ\|BPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVq4XndyUUN3ME2zO\|YvOjR3IN88US=>	NHfqb4lUSU6JRWK=
HAL-01	NXz2R4ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTN5OT64N\|gh\|ryP	Ml7oV2FPT0WU
ARH-77	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGj1SYtKSzVyPUO5OE4xODhizszN	MV7TRW5ITVJ?
MZ7-mel	M2\PRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LPXGlEPTB;M{m3MlI{OyEQvF2=	M4f5eXNCVkeHUh?=
SIMA	MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTRyMz65N\|Mh\|ryP	MV3TRW5ITVJ?
DG-75	NYK5ZXJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfkT\|k4UUN3ME20NVUvPjl6IN88US=>	NYW0WFRkW0GQR1XS
HUTU-80	Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF2ySpdKSzVyPUSxPU4yQDVizszN	MYXTRW5ITVJ?
KNS-42	M{[xSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTR{NT64NVUh\|ryP	Mm[4V2FPT0WU
SH-4	NX7ldVFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTR{Nz61OlUh\|ryP	MoX6V2FPT0WU
L-540	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTR\|MT6wN\|Eh\|ryP	NVzBeIVjW0GQR1XS
NB10	NXvnSmc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvic2lKSzVyPUS0NU4zOzRizszN	MUDTRW5ITVJ?
ES1	M2Ljb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo[2TWM2OD12NUKuO\|U{KM7:TR?=	NX3VXJp1W0GQR1XS
KMOE-2	NHTsWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonTTWM2OD12NU[uO\|EyKM7:TR?=	M{fWTHNCVkeHUh?=
MC116	MkfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\0cHZKSzVyPUS1PE4yOTZizszN	M2rzWnNCVkeHUh?=
RCC10RGB	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGG1fJVKSzVyPUS2NE4xODVizszN	NFzLVppUSU6JRWK=
RL95-2	Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTR4MD6yN\|ch\|ryP	M4i2W3NCVkeHUh?=
Raji	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1[1dWlEPTB;NE[4MlE1OyEQvF2=	M33FZnNCVkeHUh?=
CAS-1	Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTR5Mj6wO\|Mh\|ryP	NYfGZm17W0GQR1XS
Calu-6	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLsOFVsUUN3ME20O\|UvOjZ3IN88US=>	NFPsfoZUSU6JRWK=
KG-1	NGP4OohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTR5OD60OEDPxE1?	NUL0PXRiW0GQR1XS
LB771-HNC	MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\yTWM2OD12OEKuNlMzKM7:TR?=	MUDTRW5ITVJ?
ACN	M1P2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\NTWM2OD12OUOuOVk6KM7:TR?=	NEHR[XlUSU6JRWK=
KM12	NWrhRpJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTR7Nj61PFkh\|ryP	MXXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	NF-κB / Cyclin D1 / MMP2 / MMP9; PubMed: 23599805 Oncol Lett Whole cell lysates were prepared, and 50 μg proteins were resolved using SDS-PAGE, followed by immunoblotting with the indicated specific antibodies against NF-κB, cyclin D1, MMP2 and MMP9. Gli1 / TGF-β1 / CXCR4; PubMed: 26137001 Oncol Lett Western blotting demonstrated that Gli1, TGF-β1 and CXCR4 protein expression levels were downregulated in the AGS cells treated with cyclopamine for 24 h. Snail / E-cadherin / Slug / Vimentin ; PubMed: 26859575 Oncotarget SW1736 and WRO82 cells were incubated in the presence of vehicle (0.5% DMSO) or the indicated concentrations of cyclopamine or GANT61 for 72 hr. The cells were harvested and analyzed for the expression of several genes involved in EMT.	23599805 26137001 26859575
Immunofluorescence	Vimentin; PubMed: 24553082 Cancer Biol Ther Vimentin protein expression was reduced following treatment with cyclopamine (20 μmol/L; 72 h), detected by immunocytochemistry. PCNA / β-catenin; PubMed: 28747625 Sci Rep Immunofluorescence images demonstrating the distribution of PCNA or β-catenin in EH cells pre-treated with cyclopamine in presence and absence of estrogen for 24 h. Experiments were repeated at least three times.	24553082 28747625

In vivo

Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. ^[2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMO^low tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. ^[4]

Protocol

Kinase Assay:^[1]	- Collapse Hedgehog cell assay: This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO₂. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO₂. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:^[2]	- Collapse Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116 Concentrations: Dissolved in DMSO, final concentration 3 μM Incubation Time: 4 days Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD₄₉₀) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2). (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells Formulation: Dissolved in DMSO, and diluted in saline Dosages: 50 mg/kg/day Administration: Subcutaneous injection (Only for Reference)

References

[4] Feldmann G, et al. Cancer Res, 2007, 67(5), 2187-2196.

- Collapse

Solubility (25°C)

In vitro	DMF	10 mg/mL warmed (24.29 mM)
	Ethanol	2 mg/mL warmed (4.85 mM)
	DMSO	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Cyclopamine SDF

Molecular Weight	411.62
Formula	C₂₇H₄₁NO₂
CAS No.	4449-51-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	11-deoxojervine

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to reconstitute the compound for in vivo use in mice?
Answer:
One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Selective Smoothened inhibitor

PF-5274857 : Smoothened-selective, IC50=5.8 nM.
Smoothened Inhibitor in Clinical Trial

LDE225 (NVP-LDE225,Erismodegib) : Phase III for Hh-pathway activated relapsed Medulloblastoma (MB).
Newest Smoothened Inhibitor

GANT61 : Inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.
Smoothened Activator

Purmorphamine : Directly binds and activates Smoothened, and blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM.

Related Hedgehog/Smoothened Products

Smoothened Agonist (SAG) HCl ^New

Smoothened Agonist (SAG) HCl is a cell-permeable Smoothened (Smo) agonist with EC50 of 3 nM in Shh-LIGHT2 cells.
SB225002 ^New

SB225002 is a potent, and selective CXCR2 antagonist with IC50 of 22 nM for inhibiting interleukin IL-8 binding to CXCR2, > 150-fold selectivity over the other 7-TMRs tested.
SB-334867 ^New

SB-334867 is a selective orexin-1 (OX1) receptor antagonist.
Vismodegib (GDC-0449)

Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.
GANT61

GANT61 is an inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM in GLI1 expressing HEK293T cell, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.
Purmorphamine

Purmorphamine, which directly binds and activates Smoothened, blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM in HEK293T cell and also is an inducer of osteoblast differentiation with EC50 of 1 μM.
Sonidegib (NVP-LDE225)

Sonidegib (Erismodegib, NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human) in cell-free assays, respectively. Phase 3.
Taladegib (LY2940680)

Taladegib (LY2940680) binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling. Phase 1/2.
Glasdegib (PF-04449913)

Glasdegib (PF-04449913) is a potent, and orally bioavailable Smoothened (Smo) inhibitor with IC50 of 5 nM. Phase 2.
SANT-1

SANT-1 directly binds to Smoothened (Smo) receptor with K_d of 1.2 nM and inhibits Smo agonist effects with IC50 of 20 nM.

Features:Attenuates SAG stimulation of Shh-LIGHT2 cells to a greater extent relative to other antagonists.

Choose Your Country or Region

By Signaling Pathways

By product type

Cyclopamine